跳至主導覽 跳至搜尋 跳過主要內容

Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study

  • Young-Suk Lim
  • , Chun-Yen Lin
  • , Jeong Heo
  • , Ho Bae
  • , Wan-Long Chuang
  • , Tak Yin Owen Tsang
  • , Claire Fournier
  • , Aric Josun Hui
  • , Trinh Huy
  • , Susanna Tan
  • , Yang Zhao
  • , John F. Flaherty
  • , Vithika Suri
  • , Anuj Gaggar
  • , Diana Brainard
  • , Stephen Ryder
  • , Harry L. A. Janssen

研究成果: 期刊稿件文章同行評審

原文美式英語
期刊Journal of Hepatology
75
出版狀態已出版 - 2021

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

引用此